Fridays Review 2026: GLP-1 Pricing, Coaching & Insurance Support
Fridays is a GLP-1 telehealth program that bundles compounded semaglutide with 1:1 nutritionist coaching, clinician consultations, and insurance-navigation support for brand-name medications. Rolling plans run $249/month, dropping to $150/month with a 12-month prepay — the lowest committed semaglutide rate among the platforms we track as of July 2026. This review covers pricing tiers, what the coaching actually includes, and where Fridays falls short.
What Is Fridays & How Does It Work?
Fridays (joinfridays.com) positions itself as a holistic, sustainable weight loss program rather than a medication dispensary. The intake covers health history and goals, a licensed clinician reviews and prescribes where appropriate, and every subscription includes ongoing nutritionist coaching and chat support. The program supports both compounded semaglutide (oral and injectable) and brand-name medications like Ozempic and Zepbound.
That dual-track matters: most compounded GLP-1 platforms have no path to brand-name medication at all. Fridays' care team helps with insurance paperwork and prior authorizations for patients whose coverage might pay for Wegovy, Ozempic, or Zepbound — see our GLP-1 insurance coverage guide for what that process involves.
Fridays Pricing: $150-249/Month Depending on Commitment
Compounded semaglutide pricing scales with commitment length: $249/month rolling, roughly $199/month on a 3-month plan ($596), $175/month on a 6-month plan ($1,050), and $150/month on a 12-month plan ($1,800 upfront). All tiers include the same coaching and clinical bundle with no hidden membership or lab fees. Brand-name Ozempic lists at $1,498 and Zepbound at $1,828 per 28-day cycle before insurance.
The 12-month rate is the headline, but it front-loads $1,800 of risk onto a medication you may not tolerate. The monthly rate, $249, is what you should compare against other platforms' rolling prices — and there it sits mid-pack. Full landscape in our GLP-1 telehealth price comparison.
Pros & Cons of Fridays
Pros
- Cheapest committed semaglutide rate we track: $150/mo on 12-month prepay
- 1:1 nutritionist coaching bundled into every plan
- Insurance-navigation support for brand-name GLP-1s
- Oral and injectable compounded semaglutide options
- No hidden membership or lab fees
Cons
- Best pricing requires $1,800 upfront commitment
- Rolling monthly rate ($249) is mid-pack, not cheap
- No compounded tirzepatide; brand Zepbound only
- Coaching adds value only if you use it — medication-only users pay for bundle anyway
- Compounded medications are not FDA-approved
Fridays vs Other GLP-1 Telehealth Providers
Against SurpassMD, Fridays trades entry price ($249 vs $134 rolling) for coaching depth and an insurance path — full breakdown in SurpassMD vs Fridays. Against Henry Meds ($297 semaglutide) and Remedy Meds ($299), Fridays wins on price at every tier. Against TrimRx, it depends on dose: TrimRx's flat-price model beats Fridays for high-dose tirzepatide patients, while Fridays wins for committed semaglutide users. See the full best GLP-1 telehealth providers comparison.
Best for: patients who want accountability coaching alongside medication, or who suspect their insurance might cover a brand-name GLP-1 and want help finding out. Skip if: you want tirzepatide at compounded prices or the lowest possible month-one cost.
Frequently Asked Questions
As of July 2026, Fridays offers compounded semaglutide at $249/month on a rolling monthly basis, $596 for three months (about $199/month), $1,050 for six months ($175/month), or $1,800 for twelve months ($150/month). All plans include clinician consultations, prescription management, 1:1 nutritionist coaching, and chat support with no separate membership or lab fees. Brand-name Ozempic ($1,498) and Zepbound ($1,828) per 28-day cycle are available for patients wanting FDA-approved medication.
Yes, and this is one of its main differentiators. Fridays supports insurance paperwork for brand-name GLP-1 medications like Ozempic and Zepbound, including prior authorization help. Its compounded plans remain cash-pay, but if your insurance covers a brand-name GLP-1, the care team works to identify the most affordable path. Most compounded-only competitors offer no insurance support at all.
Every plan includes regular virtual clinician consultations, prescription management and renewals, 1:1 nutritionist coaching, ongoing chat support, health guides, and help with insurance coverage for brand medications. Fridays positions itself as a holistic program rather than a medication fulfillment service, and the bundle reflects that.
On a 12-month prepaid plan, mostly yes: $150/month is the lowest committed semaglutide rate among major platforms as of July 2026. On rolling monthly billing, its $249/month sits mid-pack — above SurpassMD ($134 entry) and TrimRx ($179 first month), below Henry Meds ($297) and Remedy Meds ($299). The catch with prepay is committing $1,800 upfront before you know how you tolerate the medication.
Fridays is primarily a semaglutide platform (oral and injectable compounded options), with brand-name Zepbound available for patients who want tirzepatide and can pay brand pricing or get insurance coverage. If compounded tirzepatide specifically is your goal, platforms like SurpassMD (from $199/month), TrimRx ($349 flat), Henry Meds, or Remedy Meds are more direct routes.
Only if you already know you tolerate semaglutide. A meaningful share of GLP-1 patients discontinue early due to side effects (roughly 6-7% in semaglutide trials, higher in real-world settings), and a $1,800 prepay is a poor fit for a first-time user who might stop in month two. A sensible sequence: start monthly or with a 3-month plan, confirm tolerance and results, then switch to the 12-month rate. Check refund terms for unused months before prepaying.
This page is informational and is not medical advice. This page contains a clearly-marked sponsored placement from SurpassMD, an advertising partner of Peptide Dossier; the editorial assessment of Fridays is independent of that placement. Compounded medications are not FDA-approved. Pricing verified July 2026 and subject to change.